Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2009

Lind Joline S W, Postmus Pieter E, Heideman Daniëlle A M, Thunnissen Erik B, Bekers Otto, Smit Egbert F

Abstract excerpt

Erlotinib is increasingly being used for the treatment of non-small cell lung cancer. The recommended dose is 150 mg/day and no efficacy data is available for lower doses. We describe a case of dramatic tumor response to 50 mg erlotinib in a patient with EGFR mutation positive NSCLC who developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Skin Diseases

Source

Identifiers

PMID: 20009914
DOI: 10.1097/JTO.0b013e3181bbb2b9

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20009914-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.PMID 20009914Read ↗

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.Semantic proximity Read ↗

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.Semantic proximity Read ↗

Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.Semantic proximity Read ↗

Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.Semantic proximity Read ↗

Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.Semantic proximity Read ↗

Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib.Semantic proximity Read ↗

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.Semantic proximity Read ↗

Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.Semantic proximity Read ↗

Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation.Semantic proximity Read ↗

Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.